- Exelixis Inc EXEL has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma (RCC), regardless of prior nephrectomy (surgical removal of a kidney) status.
- Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).
- The Phase 3 CheckMate-9ER evaluated Cabometyx combined with Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) versus Pfizer Inc's PFE Sutent (sunitinib).
- At a median follow-up of 23.5 months, in the patient group with prior nephrectomy, the Cabometyx combo showed a median PFS of 19.4 months versus 8.9 months in the sunitinib arm.
- Median PFS in patients without nephrectomy was 11.3 months versus 7 months.
- ORR for prior nephrectomy was 60.8% versus 30.5% and without prior nephrectomy was 41.6% vs. 23.2%
- Complete response for each patient group was (11.3% versus 6.0%) and (5.0 versus 0%) respectively.
- The duration of response was (22 months vs. 13.8 months) and (17.2 months and 9.9 months).
- Price Action: EXEL shares closed 1.69% higher at $20.47 on Wednesday.
- Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in